SIRPA and cancer: As an immune checkpoint in the myeloid-specific system, CD47 effectively protects cancer cells from phagocytosis by binding to SIRPα on phagocytic cells, thereby inhibiting the phagocytic activity of macrophages in the immune system[33,[35], [36], [37], [38]].